心电与循环
心電與循環
심전여순배
Journal of Electrocardiology(China)
2014年
1期
44-46
,共3页
血管紧张素II受体拮抗剂%缬沙坦%心房颤动%胺碘酮
血管緊張素II受體拮抗劑%纈沙坦%心房顫動%胺碘酮
혈관긴장소II수체길항제%힐사탄%심방전동%알전동
Angiotensin II receptor blockers%Valsartan%Atrial fibril ation%Amiodarone
目的观察缬沙坦联合胺碘酮对持续性心房颤动复律及复律后窦性心律维持率的影响。方法选择持续性心房颤动患者96例,随机分为两组,治疗组49例,给予缬沙坦及胺碘酮治疗,对照组47例给予安慰剂及胺碘酮治疗,随访1年,观察两组心房颤动转复率和转复后3、12个月时心房颤动复发率,以及转复时及转复后12个月左心房内径(LAD)、左心室射血分数(LVEF)变化。结果心房颤动转复率治疗组(87.8%)与对照组(85.1%)差异无统计学意义(P>0.05),心房颤动复发率转复后3个月及12个月治疗组(14.0%、23.2%)均小于对照组(32.5%、54.5%)(P<0.05或0.01),转律后12个月LAD治疗组[(44.3±0.65)mm)]较对照组[(46.9±0.54)mm]变小(P<0.05),LVEF治疗组[(56.8±8.64)%]较对照组[(52.3±9.08)%]升高(P<0.05)。结论缬沙坦联合胺碘酮治疗持续性心房颤动在减少心房颤动的复发率以及改善心功能方面优于单独使用胺碘酮。
目的觀察纈沙坦聯閤胺碘酮對持續性心房顫動複律及複律後竇性心律維持率的影響。方法選擇持續性心房顫動患者96例,隨機分為兩組,治療組49例,給予纈沙坦及胺碘酮治療,對照組47例給予安慰劑及胺碘酮治療,隨訪1年,觀察兩組心房顫動轉複率和轉複後3、12箇月時心房顫動複髮率,以及轉複時及轉複後12箇月左心房內徑(LAD)、左心室射血分數(LVEF)變化。結果心房顫動轉複率治療組(87.8%)與對照組(85.1%)差異無統計學意義(P>0.05),心房顫動複髮率轉複後3箇月及12箇月治療組(14.0%、23.2%)均小于對照組(32.5%、54.5%)(P<0.05或0.01),轉律後12箇月LAD治療組[(44.3±0.65)mm)]較對照組[(46.9±0.54)mm]變小(P<0.05),LVEF治療組[(56.8±8.64)%]較對照組[(52.3±9.08)%]升高(P<0.05)。結論纈沙坦聯閤胺碘酮治療持續性心房顫動在減少心房顫動的複髮率以及改善心功能方麵優于單獨使用胺碘酮。
목적관찰힐사탄연합알전동대지속성심방전동복률급복률후두성심률유지솔적영향。방법선택지속성심방전동환자96례,수궤분위량조,치료조49례,급여힐사탄급알전동치료,대조조47례급여안위제급알전동치료,수방1년,관찰량조심방전동전복솔화전복후3、12개월시심방전동복발솔,이급전복시급전복후12개월좌심방내경(LAD)、좌심실사혈분수(LVEF)변화。결과심방전동전복솔치료조(87.8%)여대조조(85.1%)차이무통계학의의(P>0.05),심방전동복발솔전복후3개월급12개월치료조(14.0%、23.2%)균소우대조조(32.5%、54.5%)(P<0.05혹0.01),전률후12개월LAD치료조[(44.3±0.65)mm)]교대조조[(46.9±0.54)mm]변소(P<0.05),LVEF치료조[(56.8±8.64)%]교대조조[(52.3±9.08)%]승고(P<0.05)。결론힐사탄연합알전동치료지속성심방전동재감소심방전동적복발솔이급개선심공능방면우우단독사용알전동。
Objective To investigate the effect of Valsartan combined with Amiodarone on cardioversion of persistant atrial fibrillation (AF) and maintenance of sinus rhythm after cardioversion. Methods 96 patients with permanent AF were randomly divided into control group(n=47) and Valsartan group (n=49). The conversion rate of AF at one year and reoccur-rence of AF at 3 and 12 months after cardioversion were investigated. Left atrial dimension and left ventricular ejection frac-tion (LVEF) were measured at the moment of cardioversion and 12 months after cardioversion. Results The rate of AF cardioversion was not significant difference between two groups (87.8%vs 85.1%, P>0.05). The recurrence rate was sig-nificantly lower in Valsartan group than control group at 3 months (14.0% vs 32.5%, P<0.05) and 12 months (23.2% vs 54.5%, P<0.01). Left atrium significantly decreased (44.3 ±0.65 mm vs 46.9 ±0.54 mm, P<0.05) and LVEF increased (56.8±8.64%vs 52.3±9.08%, P<0.05) in Valsartan group at 12 months. Conclusion Valsartan with Amiodarone is su-perior to Amiodarone alone in maintaining sinus rhythm and improving heart function in the patients with permanent AF.